227 related articles for article (PubMed ID: 17553880)
1. Replication-competent recombinant vesicular stomatitis virus encoding hepatitis C virus envelope proteins.
Tani H; Komoda Y; Matsuo E; Suzuki K; Hamamoto I; Yamashita T; Moriishi K; Fujiyama K; Kanto T; Hayashi N; Owsianka A; Patel AH; Whitt MA; Matsuura Y
J Virol; 2007 Aug; 81(16):8601-12. PubMed ID: 17553880
[TBL] [Abstract][Full Text] [Related]
2. Characterization of pseudotype VSV possessing HCV envelope proteins.
Matsuura Y; Tani H; Suzuki K; Kimura-Someya T; Suzuki R; Aizaki H; Ishii K; Moriishi K; Robison CS; Whitt MA; Miyamura T
Virology; 2001 Aug; 286(2):263-75. PubMed ID: 11485395
[TBL] [Abstract][Full Text] [Related]
3. Coexpression of hepatitis C virus E1 and E2 chimeric envelope glycoproteins displays separable ligand sensitivity and increases pseudotype infectious titer.
Meyer K; Beyene A; Bowlin TL; Basu A; Ray R
J Virol; 2004 Dec; 78(23):12838-47. PubMed ID: 15542636
[TBL] [Abstract][Full Text] [Related]
4. Development of an infectious surrogate hepatitis C virus based on a recombinant vesicular stomatitis virus expressing hepatitis C virus envelope glycoproteins and green fluorescent protein.
Okuma K; Fukagawa K; Tateyama S; Kohma T; Mochida K; Hiyoshi M; Takahama Y; Hamaguchi Y; Hirose K; Buonocore L; Rose JK; Mizuochi T; Hamaguchi I
Jpn J Infect Dis; 2015; 68(3):203-8. PubMed ID: 25672345
[TBL] [Abstract][Full Text] [Related]
5. Efficient formation of vesicular stomatitis virus pseudotypes bearing the native forms of hepatitis C virus envelope proteins detected after sonication.
Tamura K; Oue A; Tanaka A; Shimizu N; Takagi H; Kato N; Morikawa A; Hoshino H
Microbes Infect; 2005 Jan; 7(1):29-40. PubMed ID: 15716060
[TBL] [Abstract][Full Text] [Related]
6. Reduction of the infectivity of hepatitis C virus pseudoparticles by incorporation of misfolded glycoproteins induced by glucosidase inhibitors.
Chapel C; Garcia C; Bartosch B; Roingeard P; Zitzmann N; Cosset FL; Dubuisson J; Dwek RA; Trépo C; Zoulim F; Durantel D
J Gen Virol; 2007 Apr; 88(Pt 4):1133-1143. PubMed ID: 17374756
[TBL] [Abstract][Full Text] [Related]
7. Functional role of hepatitis C virus chimeric glycoproteins in the infectivity of pseudotyped virus.
Lagging LM; Meyer K; Owens RJ; Ray R
J Virol; 1998 May; 72(5):3539-46. PubMed ID: 9557633
[TBL] [Abstract][Full Text] [Related]
8. Evaluating replication-defective vesicular stomatitis virus as a vaccine vehicle.
Majid AM; Ezelle H; Shah S; Barber GN
J Virol; 2006 Jul; 80(14):6993-7008. PubMed ID: 16809305
[TBL] [Abstract][Full Text] [Related]
9. Sulfated homologues of heparin inhibit hepatitis C virus entry into mammalian cells.
Basu A; Kanda T; Beyene A; Saito K; Meyer K; Ray R
J Virol; 2007 Apr; 81(8):3933-41. PubMed ID: 17287282
[TBL] [Abstract][Full Text] [Related]
10. Hepatitis C virus E1 envelope glycoprotein interacts with apolipoproteins in facilitating entry into hepatocytes.
Mazumdar B; Banerjee A; Meyer K; Ray R
Hepatology; 2011 Oct; 54(4):1149-56. PubMed ID: 21735466
[TBL] [Abstract][Full Text] [Related]
11. Entry of hepatitis C virus pseudotypes into primary human hepatocytes by clathrin-dependent endocytosis.
Codran A; Royer C; Jaeck D; Bastien-Valle M; Baumert TF; Kieny MP; Pereira CA; Martin JP
J Gen Virol; 2006 Sep; 87(Pt 9):2583-2593. PubMed ID: 16894197
[TBL] [Abstract][Full Text] [Related]
12. Analysis of Lujo virus cell entry using pseudotype vesicular stomatitis virus.
Tani H; Iha K; Shimojima M; Fukushi S; Taniguchi S; Yoshikawa T; Kawaoka Y; Nakasone N; Ninomiya H; Saijo M; Morikawa S
J Virol; 2014 Jul; 88(13):7317-30. PubMed ID: 24741091
[TBL] [Abstract][Full Text] [Related]
13. Generation of hepatitis C virus-like particles by use of a recombinant vesicular stomatitis virus vector.
Ezelle HJ; Markovic D; Barber GN
J Virol; 2002 Dec; 76(23):12325-34. PubMed ID: 12414973
[TBL] [Abstract][Full Text] [Related]
14. The hypervariable region 1 of the E2 glycoprotein of hepatitis C virus binds to glycosaminoglycans, but this binding does not lead to infection in a pseudotype system.
Basu A; Beyene A; Meyer K; Ray R
J Virol; 2004 May; 78(9):4478-86. PubMed ID: 15078928
[TBL] [Abstract][Full Text] [Related]
15. A novel small molecule inhibitor of hepatitis C virus entry.
Baldick CJ; Wichroski MJ; Pendri A; Walsh AW; Fang J; Mazzucco CE; Pokornowski KA; Rose RE; Eggers BJ; Hsu M; Zhai W; Zhai G; Gerritz SW; Poss MA; Meanwell NA; Cockett MI; Tenney DJ
PLoS Pathog; 2010 Sep; 6(9):e1001086. PubMed ID: 20838466
[TBL] [Abstract][Full Text] [Related]
16. Influence of N-linked glycans on intracellular transport of hepatitis C virus E1 chimeric glycoprotein and its role in pseudotype virus infectivity.
Beyene A; Basu A; Meyer K; Ray R
Virology; 2004 Jul; 324(2):273-85. PubMed ID: 15207615
[TBL] [Abstract][Full Text] [Related]
17. Functional features of hepatitis C virus glycoproteins for pseudotype virus entry into mammalian cells.
Meyer K; Basu A; Ray R
Virology; 2000 Oct; 276(1):214-26. PubMed ID: 11022009
[TBL] [Abstract][Full Text] [Related]
18. Cross-reactive pseudovirus-neutralizing anti-envelope antibodies coexist with antibodies devoid of such activity in persistent hepatitis C virus infection.
Burioni R; Mancini N; Carletti S; Perotti M; Grieco A; Canducci F; Varaldo PE; Clementi M
Virology; 2004 Oct; 327(2):242-8. PubMed ID: 15351212
[TBL] [Abstract][Full Text] [Related]
19. Formation of vesicular stomatitis virus pseudotypes bearing surface proteins of hepatitis B virus.
Saha MN; Tanaka A; Jinno-Oue A; Shimizu N; Tamura K; Shinagawa M; Chiba J; Hoshino H
J Virol; 2005 Oct; 79(19):12566-74. PubMed ID: 16160184
[TBL] [Abstract][Full Text] [Related]
20. Diverging effects of human recombinant anti-hepatitis C virus (HCV) antibody fragments derived from a single patient on the infectivity of a vesicular stomatitis virus/HCV pseudotype.
Burioni R; Matsuura Y; Mancini N; Tani H; Miyamura T; Varaldo PE; Clementi M
J Virol; 2002 Nov; 76(22):11775-9. PubMed ID: 12388741
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
